以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 | 交易日 | 持股总数(股) | 持股变动(股) | 变动幅度 | | --- | --- | --- | --- | | 2025-10-22 | 7944.90万 | -7.20万 | -0.09% | | 2025-10-21 | 7952.10万 | -33.60万 | -0.42% | | 2025-10-20 | 7985.70万 | -21.00万 | -0.26% | | 2025-10-17 | 8006.70万 | -1.20万 | -0.01% | | 2025-10-16 | 8007.90万 | -4000.0 | -0.00% | 希玛医疗控股有限公司（原名：希玛眼科医疗控股有限公司）是一家主要从事提供医疗服务业务的投资 控股公司。该公司通过四个部门运营业务。香港医疗业务分部主要从事在香港提供眼科、牙科及其他医 疗服务以及销售视力辅助产品业务。内地牙科业务分部主要从事在内地提供牙科服务业务。销售医疗耗 材分部主要从事在香港销售医疗耗材业务。内地眼科业务分部 ...

证券之星消息，10月15日南向资金减持8.8万股希玛医疗（03309.HK）。近5个交易日中，获南向资金减 持的有5天，累计净减持124.2万股。近20个交易日中，获南向资金减持的有20天，累计净减持344.0万 股。截至目前，南向资金持有希玛医疗（03309.HK）8008.3万股，占公司已发行普通股的6.37%。 希玛医疗控股有限公司（原名：希玛眼科医疗控股有限公司）是一家主要从事提供医疗服务业务的投资 控股公司。该公司通过四个部门运营业务。香港医疗业务分部主要从事在香港提供眼科、牙科及其他医 疗服务以及销售视力辅助产品业务。内地牙科业务分部主要从事在内地提供牙科服务业务。销售医疗耗 材分部主要从事在香港销售医疗耗材业务。内地眼科业务分部主要从事在内地提供眼科服务及销售视力 辅助产品业务。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 | 交易日 | 持股总数(股) | 持股变动(股) | 变动幅度 | | --- | --- | --- | --- | | 2025-10-15 | 8008.30万 | -8.80万 | - ...

盈健医疗(01419)公布截至2025年6月30日止年度业绩，收益约为6.444亿港元，同比增加约9.1%。公司拥 有人应占溢利约为2630万港元，同比增长约8.9%。每股基本盈利约为6.9港仙，末期股息3.0港仙。 公告称，溢利增加主要由于全科医疗服务、专科医疗服务及牙科服务收益增长;及毛利增加，此乃由于 收益增长所致。 ...

格隆汇9月25日丨盈健医疗(01419.HK)公告，集团于2025财年收益约为6.44亿港元，同比增加约9.1%。 公司拥有人应占溢利约为2630万港元，同比增加约8.9%。每股基本盈利约为6.9港仙(2024财年：约6.4港 仙)。董事会建议宣派2025财年末期股息3.0港仙(2024财年：2.8港仙)。 尽管香港经济持续面临不利因素，集团灵活应对该等挑战，2025财年收益较2024财年实现稳健增长，公 司拥有人应占溢利同比增长约8.9%。集团核心业务分部保持均衡增长。在网络扩展及强大病人群的推 动下，全科医疗分部表现稳定。受惠于服务升级及更多专科医生的加入，尤其是眼科、小儿外科、心脏 科、精神科及骨科，专科医疗分部实现稳健收益增长。同时，尽管牙科分部面临竞争压力，但随着于 2025财年完成收购佑德牙科，该分部实现整体收益增长。 ...

公告称，溢利增加主要由于全科医疗服务、专科医疗服务及牙科服务收益增长;及毛利增加，此乃由于 收益增长所致。 智通财经APP讯，盈健医疗(01419)公布截至2025年6月30日止年度业绩，收益约为6.444亿港元，同比增 加约9.1%。公司拥有人应占溢利约为2630万港元，同比增长约8.9%。每股基本盈利约为6.9港仙，末期 股息3.0港仙。 ...

Core Viewpoint - Modern Dental Group reported a revenue of HKD 1.835 billion for the six months ending June 30, 2025, representing a year-on-year increase of 7.81% [1] - The profit attributable to the company's owners was HKD 285 million, a significant year-on-year increase of 32.52% [1] - The company plans to distribute an interim dividend of HKD 0.107 per share [1] Revenue Growth Drivers - The revenue growth was primarily driven by sustained organic growth in Europe and Australia [1] - The completion of the acquisition of Thailand's largest dental laboratory, Hexa Ceram Company Limited, in January 2025 accelerated the group's growth [1]

Core Viewpoint - Hema Medical (03309) reported a revenue increase of 2.4% year-on-year, driven by rising demand for ophthalmic medical services in Hong Kong, despite competitive pressures in Shenzhen affecting dental and ophthalmic service revenues [1] Financial Performance - Revenue for the first half of 2025 reached HKD 944 million, reflecting a year-on-year growth of 2.4% [1] - Profit attributable to equity holders amounted to HKD 49.94 million, showing a significant year-on-year increase of 62.4% [1] Market Dynamics - The growth in revenue was primarily attributed to increased demand for ophthalmic services in the Hong Kong market, which was partially offset by decreased revenues in Shenzhen due to intense competition in dental and ophthalmic services [1] Acquisition Announcement - Hema Medical announced the acquisition of 58% of the issued share capital of Hong Kong Endoscopy Examination and Treatment Centre Limited, which operates under the name "Hong Kong Endoscopy Centre" [1] - The acquisition is expected to be completed around October 2025 [1]

Core Viewpoint - Hema Medical (03309) reported a 6.5% increase in stock price, reaching HKD 2.13, with a trading volume of HKD 6.7167 million following the release of its mid-year results for 2025 [1] Financial Performance - The company reported revenue of HKD 944 million for the first half of 2025, representing a year-on-year growth of 2.4% [1] - Profit attributable to equity holders was HKD 49.944 million, showing a significant year-on-year increase of 62.4% [1] Market Dynamics - The slight increase in revenue was attributed to rising demand for ophthalmic medical services in Hong Kong, which boosted revenue from ophthalmic services [1] - However, this growth was partially offset by a decline in revenue from dental and ophthalmic services in Shenzhen due to intense competition [1] Acquisition Announcement - Hema Medical announced an agreement to acquire 58% of the issued share capital of Hong Kong Endoscopy Examination and Treatment Centre Limited, which operates under the name "Hong Kong Endoscopy Centre" [1] - The acquisition is expected to be completed around October 2025 [1]

Core Viewpoint - The company reported a slight increase in revenue driven by the growing demand for ophthalmic medical services in Hong Kong, although this was partially offset by a decrease in revenue from dental and ophthalmic services in Shenzhen due to intense competition [1] Financial Performance - Revenue for the six months ending June 30, 2025, was HKD 944 million, representing a year-on-year growth of 2.4% [1] - Profit attributable to equity holders was HKD 49.944 million, showing a significant year-on-year increase of 62.4% [1] - Basic earnings per share were HKD 0.0411 [1] Market Dynamics - The increase in revenue was primarily attributed to the rising demand for ophthalmic services in the Hong Kong market [1] - The decline in revenue from Shenzhen's dental and ophthalmic services was a result of fierce competition in that region [1]

Group 1 - The company has a total of 38 hospitals in its medical sector, with 32 of them being rehabilitation hospitals focused on severe rehabilitation [2] - The subsidiary Ningbo Mingzhou Hospital is a tertiary Class B comprehensive hospital with over 40 departments, including dental, ophthalmology, and medical aesthetics [2]